Rectal controlled-release morphine: Plasma levels of morphine and its metabolites following the rectal administration of MST Continus 100 MG

Journal of Clinical Pharmacy and Therapeutics

Volumn 21, Issue 2, 1996, Pages 65-71

  Campbell, W I ^a  

^a ULSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE;

ADULT; ANESTHESIA INDUCTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; DRUG UPTAKE; FEMALE; GENERAL ANESTHESIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXILLA OSTEOTOMY; PHARMACEUTICS; POSTOPERATIVE PAIN; RECTAL DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION;

EID: 0029898955     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.1996.tb00002.x     Document Type: Article

References (29)

1. Hanks GW, Hoskin PJ. (1987) Opioid analgesics in the management of pain in patients with cancer: A review. Palliative Medicine, 1, 1-25.
2. Christensen CB, Jorgensen LN. (1987) Morphine-6-glucuronide has high affinity for the opioid receptor. Pharmacology and Toxicology, 60, 75-76.
3. Osborne R, Joel S, Trew D, Slevin M. (1988) Analgesic activity of morphine-6-glucuronide. Lancet, i, 828.
4. Shimomura K, Kamato O, Ueki S, Ida S, Oguri K, Yoshimura H, Tsukamoto H. (1971) Analgesic effects of morphine glucuronides. Tohoku Journal of Experimental Medicine, 105, 45-52.
5. McQuay HJ. (1991) Opioid clinical pharmacology and routes of administration. British Medical Bulletin, 47, 703-717.
6. Hanks GW, Aherne GE, Hoskin PJ, Tumor P. (1987) Explanation for potency of repeated oral doses of morphine. Lancet, ii, 723-725.
7. Cole L, Hanning CD. (1990) Issues in drug management. Review of the rectal use of opioids. Journal of Pain and Symptom Management, 5, 118-126.
8. De Boer AG, de Leede LGJ, Breimer DD. (1984) Drug absorption by sublingual and rectal routes. British Journal of Anaesthesia, 56, 69-82.
9. Westerling D, Andersson K.-E. (1984) Rectal administration of morphine hydrogel: Absorption and bioavailability in women. Acta Anaesthesilogica Scandinavica, 28, 540-543.
10. Moolenaar F, Yska JP, Visser J, Meijer DKF. (1985) Drastic improvement in the rectal absorption profile of morphine in man. European Journal of Clinical Pharmacology, 29, 119-121.
11. Clarke RSJ. (1984) Nausea and vomiting. British Journal of Anaesthesia, 56, 19-27.
12. Jonsson T, Christensen CB, Jordening H, Frolund C. (1988) The bioavailability of rectally administered morphine. Pharmacology and Toxicology, 62, 203-205.
13. Kaiko RF, Fitzmartin RD, Thomas GB, Goldenheim PD. (1992) The bioavailability of morphine in controlled-release 30 mg tablets per rectum compared with immediate-release 30 mg rectal suppositories and controlled-release 30 mg oral tablets. Pharmacotherapy, 12, 107-113.
14. Todd RD, Muldoon SM, Watson RL. (1982) Determination of morphine in cerebrospinal fluid and plasma by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography, 232, 101-110.
15. Simpson KH, Dearden MJ, Ellis FR, Jack TM. (1988) Premedication with slow release morphine (MST) and adjuvants. British Journal of Anaesthesia, 60, 825-830.
16. Maloney CM, Kesner RK, Klein G, Bockenstette J. (1989) The rectal administration of MS Contin: Clinical implications of use in end stage cancer. American Journal of Hospice Care, 6, 34-35.
17. Westerling D, Lindahl S, Andersson K.-E., Andersson A. (1982) Absorption and bioavailability of rectally administered morphine in women. European Journal of Clinical Pharmacology, 23, 59-64.
18. Portenoy RK, Foley KM, Stulman J, Khan E, Adelhardt J, Lyman M, Cerbone DF, Inturrisi CE. (1991) Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: Plasma profiles, steady-state concentrations and the consequences of renal failure. Pain, 47, 13-19.
19. Sear JW, Hand CW, Moore RA, McQuay HJ. (1989) Studies on morphine disposition: Influence of renal failure on the kinetics of morphine and its metabolites. British Journal of Anaesthesia, 62, 28-32.
20. Woolf CJ. (1981) Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Research, 209, 491-495.
21. Yaksh TL, Harty GJ, Onofrio BM. (1986) High doses of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: Clinical and theoretic implications. Anesthesiology, 64, 590-597.
22. Smith GD, Smith MT. (1995) Morphine-3-glucuronide: Evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Pain, 62, 51-60.
23. Smith MT, Watt JA, Cramond T. (1990) Morphine-3-glucuronide: A potent antagonist of morphine analgesia. Life Sciences, 47, 579-585.
24. Gong QL, Hedner J, Bjorkman R, Hedner I. (1992) Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain, 48, 249-255.
25. Wilkinson TJ, Robinson BA, Begg EJ, Duffull SB, Ravenscroft PJ, Schneider JJ. (1992) Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. Cancer Chemotherapy and Pharmacology, 31, 251-254.
26. Goucke CR, Hackett LP, Ilett KF. (1994) Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain. Pain, 56, 145-149.
27. Bartlett SE, Dodd PR, Smith MT. (1994) Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites. Pharmacology and Toxicology, 75, 73-81.
28. Hanks GW, Rose NM, Aherne GW, Piall EM, Fairfield S, Trueman T. (1980) Controlled-release morphine tablets. A double-blind trial in dental surgery patients. British Journal of Anaesthesia, 53, 1259-1264.
29. Vater M, Smith G, Aherne GW, Aitkenhead AR. (1984) Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers. British Journal of Anaesthesia, 56, 821-827.